Key result
Quantitative assessment of new oral anticoagulants may be needed in emergency situations, such as serious bleeding or urgent surgery, or in patients with renal or hepatic insufficiency.
While new oral anticoagulants do not require routine monitoring, coagulation testing may be necessary in emergency situations like serious bleeding, urgent surgery, or organ insufficiency.
May warrant selective quantitative testing in NOAC emergencies or organ failure; leaves open assay standardization and validation.
Atrial fibrillation is the most common and important cardiac rhythm disorder, which increases the risk of stroke and mortality. New oral anticoagulants are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation. New oral anticoagulants do not require routine monitoring of coagulation. However, the quantitative assessment of the anticoagulant effect drug levels may be needed in emergency situations, such as a serious bleeding or need for urgent surgery, or in patient with renal or hepatic insufficiency. In the paper we focus on the coagulation testing for new oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Mehmet Demir (2015) conducted a review in Atrial fibrillation. Coagulation testing for new oral anticoagulants was evaluated. Quantitative assessment of new oral anticoagulants may be needed in emergency situations, such as serious bleeding or urgent surgery, or in patients with renal or hepatic insufficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: